MAPT and early-onset autosomal dominant Alzheimer disease: PET is a key technology in modern Alzheimer’s disease clinical trials for confirming clearance of pathology (amyloid and tau protein aggregates)2-4 and for trial eligibility.4 Both scenarios require a biomarker to be defined for the quantification of pathology.